NEWS & EVENTS

 

ADC Therapeutics raises $200m to advance antibody-based cancer treatments

 
ADC Therapeutics raises $200m to advance antibody-based cancer treatments

27 October 2017

Our client, ADC Therapeutics (ADCT), has raised $200m in private financing to fund registrational trials of its two lead cancer programs. Investors include: Auven Therapeutics, Redmile, the Wild Family Office and its development partner AstraZeneca.

The Swiss based company develops antibody drug conjugates that target major cancers by incorporating highly potent pyrrolobenzodiazepine-based warheads. Its clinical and preclinical programs target major forms of hematological malignancies and solid tumours.

Earlier this month, ADCT triggered a second target-specific license with Netherlands-based biotechnology company, Synaffix, to develop an antibody-drug conjugate using Synaffix’s proprietary site-specific antibody-drug conjugation technology.

Read the full article.

Robert Andrews and Robert Watson lead the patent team working with ADC Therapeutics on their IP portfolio.